bioMérieux, a firm that designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination, agreed to acquire Specific Diagnostics, a developer of rapid antimicrobial susceptibility test system. Financial terms were not disclosed. “This acquisition reinforces our long-standing commitment to sustain antibiotic efficacy for future generations. With the addition of Specific Diagnostics’ REVEAL Rapid AST system into our microbiology portfolio, bioMérieux further supports clinicians and laboratories in further improving patient outcomes and enhancing antimicrobial stewardship, leveraging our extensive distribution network," Alexandre Mérieux, bioMérieux Chairman and CEO.